Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Zaja

Showing results (51-60 of 145) with videos related to

Pageof 15
Sort By:
British Journal of Haematology|June 28, 2024
Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana LinfomiFederica Cavallo, Michele Clerico, Elisa Lucchini, et al.
The Oncologist|February 25, 2011
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combinationAndrés J M Ferreri, Giada Licata, Marco Foppoli, et al.
Neurology|March 18, 2014
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 yearsAndrés J M Ferreri, Fabio Ciceri, Alba A Brandes, et al.
European Journal of Haematology|December 17, 2016
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term responseMiriam Marangon, Nicola Vianelli, Francesca Palandri, et al.
Haematologica|June 17, 2021
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute studySimon Rule, Wolney Gois Barreto, Javier Briones, et al.
Haematologica|November 13, 2012
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 yearsNicola Vianelli, Francesca Palandri, Nicola Polverelli, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2004
Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trialMichele Reni, Warren Mason, Francesco Zaja, et al.
Leukemia & Lymphoma|September 23, 2014
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practicePier Luigi Zinzani, Luigi Rigacci, Maria Cristina Cox, et al.
Therapeutic Advances in Hematology|October 14, 2021
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendationsMonica Carpenedo, Erminia Baldacci, Claudia Baratè, et al.
Cancer|July 7, 2011
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced diseaseAlessandra Tedeschi, Giulia Benevolo, Marzia Varettoni, et al.
Pageof 15

Showing results (51-60 of 145) with videos related to

Sort By:
Pageof 15
British Journal of Haematology|June 28, 2024
Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana LinfomiFederica Cavallo, Michele Clerico, Elisa Lucchini, et al.
The Oncologist|February 25, 2011
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combinationAndrés J M Ferreri, Giada Licata, Marco Foppoli, et al.
Neurology|March 18, 2014
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 yearsAndrés J M Ferreri, Fabio Ciceri, Alba A Brandes, et al.
European Journal of Haematology|December 17, 2016
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term responseMiriam Marangon, Nicola Vianelli, Francesca Palandri, et al.
Haematologica|June 17, 2021
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute studySimon Rule, Wolney Gois Barreto, Javier Briones, et al.
Haematologica|November 13, 2012
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 yearsNicola Vianelli, Francesca Palandri, Nicola Polverelli, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2004
Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trialMichele Reni, Warren Mason, Francesco Zaja, et al.
Leukemia & Lymphoma|September 23, 2014
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practicePier Luigi Zinzani, Luigi Rigacci, Maria Cristina Cox, et al.
Therapeutic Advances in Hematology|October 14, 2021
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendationsMonica Carpenedo, Erminia Baldacci, Claudia Baratè, et al.
Cancer|July 7, 2011
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced diseaseAlessandra Tedeschi, Giulia Benevolo, Marzia Varettoni, et al.
Pageof 15